bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 2 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Authors: Sum Eva , Rapp Moritz , Fröbel Philipp , Le Clech Marine , Dürr Harald , Giusti Anna Maria , Perro Mario , Speziale Dario , Kunz Leo , Menietti Elena , Brünker Peter , Hopfer Ulrike , Lechmann Martin , Sobieniecki Andrzej , Appelt Birte , Adelfio Roberto , Nicolini Valeria , Freimoser-Grundschober Anne , Jordaan Whitney , Labiano Sara , Weber Felix , Emrich Thomas , Christen François , Essig Birgit , Romero Pedro , Trumpfheller Christine , Umaña Pablo
Published: April 2023

List of all genes analyzed in NanoString gene expression analysis comparing gene expression in tumors of selicrelumab and FAP-huCD40-treated mice
Supplementary Table S4b from Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Authors: Udayakumar Durga , Zhang Ze , Xi Yin , Dwivedi Durgesh K. , Fulkerson Michael , Haldeman Sydney , McKenzie Tiffani , Yousuf Qurratulain , Joyce Allison , Hajibeigi Asghar , Notgrass Hollis , de Leon Alberto Diaz , Yuan Qing , Lewis Matthew A. , Madhuranthakam Ananth J. , Sibley Robert C. , Elias Roy , Guo Junyu , Christie Alana , McKay Renée M. , Cadeddu Jeffrey A. , Bagrodia Aditya , Margulis Vitaly , Brugarolas James , Wang Tao , Kapur Payal , Pedrosa Ivan
Published: April 2023

DCE-NG vs. Normalized Gene expression
Supplementary Figures 1-6 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Authors: Sum Eva , Rapp Moritz , Fröbel Philipp , Le Clech Marine , Dürr Harald , Giusti Anna Maria , Perro Mario , Speziale Dario , Kunz Leo , Menietti Elena , Brünker Peter , Hopfer Ulrike , Lechmann Martin , Sobieniecki Andrzej , Appelt Birte , Adelfio Roberto , Nicolini Valeria , Freimoser-Grundschober Anne , Jordaan Whitney , Labiano Sara , Weber Felix , Emrich Thomas , Christen François , Essig Birgit , Romero Pedro , Trumpfheller Christine , Umaña Pablo
Published: April 2023

Supplementary Figure 1 shows more details on the mode of action and design of the used antibodies. Supplementary Figure 2 displays additional APC activation data of the human and murine FAP-CD40 molecules. Supplementary Figure 3 shows additional data for FRC in vitro assays and the OVA vaccination study. Supplementary Figure 4 shows additional data on the in vivo study comparing FAP-huCD40 and SGN40 moIgG1. Supplementary Figure 5 displays additional data on the in vivo comparison of selicrelumab and FAP-huCD40. Supplementary Figure 6 shows the data of a FAP-huCD40 dose escalation study in cynomolgus monkeys.
Table S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Authors: Segal Neil H. , Cercek Andrea , Ku Geoffrey , Wu Abraham J. , Rimner Andreas , Khalil Danny N. , Reidy-Lagunes Diane , Cuaron John , Yang T. Jonathan , Weiser Martin R. , Romesser Paul B. , Stadler Zsofia K. , Varghese Anna M. , Ganesh Karuna , Yaeger Rona , Connell Louise C. , Faleck David , Abou-Alfa Ghassan K. , Mcauliffe Kathleen C. , Vaiskauskas Pamela , Solter Mark L. , Ogle Martinique , Adamow Matthew J. , Holland Aliya , Vedantam Pallavi , Wong Phillip , Merghoub Taha , Vakiani Efsevia , Hollmann Travis J. , Juluru Krishna , Chou Joanne F. , Capanu Marinela , Erinjeri Joseph , Solomon Stephen , Yamada Yoshiya , Kemeny Nancy , Crane Christopher H. , Saltz Leonard B.
Published: April 2023

Treatment-related adverse events
Supplementary Figures from Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Authors: Brase Jan C. , Walter Robert F.H. , Savchenko Alexander , Gusenleitner Daniel , Garrett James , Schimming Tobias , Varaljai Renata , Castelletti Deborah , Kim Ju , Dakappagari Naveen , Schultz Ken , Robert Caroline , Long Georgina V. , Nathan Paul D. , Ribas Antoni , Flaherty Keith T. , Karaszewska Boguslawa , Schachter Jacob , Sucker Antje , Schmid Kurt W. , Zimmer Lisa , Livingstone Elisabeth , Gasal Eduard , Schadendorf Dirk , Roesch Alexander
Published: April 2023

Supplementary Figures from Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Figure S7 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses by HPV- and cN, DeepPET-OPSCC risk category, entire cohort
Supplementary Figure S2 from Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia
Authors: Zhang Hui , Wang Pengfei , Li Zhuoyan , He Yingyi , Gan Wenting , Jiang Hua
Published: April 2023

Supplementary Figure S2. The lymphocyte population before anti-CLL1 CAR-T cell therapy among these four R/R-AML patients.
Supplementary Figure S1 from Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia
Authors: Zhang Hui , Wang Pengfei , Li Zhuoyan , He Yingyi , Gan Wenting , Jiang Hua
Published: April 2023

Supplementary Figure S1. The flow-chart of CALSIII-AML 18 and our study.
Supplementary Figure S2 from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
Authors: Loree Jonathan M. , Wang Yucai , Syed Muddassir A. , Sorokin Alexey V. , Coker Oluwadara , Xiu Joanne , Weinberg Benjamin A. , Vanderwalde Ari M. , Tesfaye Anteneh , Raymond Victoria M. , Miron Benjamin , Tarcic Gabi , Zelichov Ori , Broaddus Russell R. , Ng Patrick Kwok Shing , Jeong Kang Jin , Tsang Yiu Huen , Mills Gordon B. , Overman Michael J. , Grothey Axel , Marshall John L. , Kopetz Scott
Published: April 2023

Comparison of (A) cell viability and (B) protein expression levels as assessed by reverse phase protein arrays in Ba/F3 transformation assay demonstrating (C) a lack of correlation between protein level and transformation, supporting that functional status rather than protein level are driving cellular transformation.
Table S5 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

Clinical data for patients receiving genomically-matched therapy following PD-1 progression.
Table S4 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

Univariate analysis of TTF outcomes to PD-1 monotherapy.
Supplemental Figure S3 from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
Authors: Loree Jonathan M. , Wang Yucai , Syed Muddassir A. , Sorokin Alexey V. , Coker Oluwadara , Xiu Joanne , Weinberg Benjamin A. , Vanderwalde Ari M. , Tesfaye Anteneh , Raymond Victoria M. , Miron Benjamin , Tarcic Gabi , Zelichov Ori , Broaddus Russell R. , Ng Patrick Kwok Shing , Jeong Kang Jin , Tsang Yiu Huen , Mills Gordon B. , Overman Michael J. , Grothey Axel , Marshall John L. , Kopetz Scott
Published: April 2023

Western blot of RAS expression and accompanying RAS-GTP pulldown assay for isogenic SW48 cell lines generated for xenograft experiments.
Supplementary Methods from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Authors: Weiss Sarah A. , Djureinovic Dijana , Jessel Shlomit , Krykbaeva Irina , Zhang Lin , Jilaveanu Lucia , Ralabate Amanda , Johnson Barbara , Levit Neta Shanwetter , Anderson Gail , Zelterman Daniel , Wei Wei , Mahajan Amit , Trifan Ovid , Bosenberg Marcus , Kaech Susan M. , Perry Curtis J. , Damsky William , Gettinger Scott , Sznol Mario , Hurwitz Michael , Kluger Harriet M.
Published: April 2023

Supplementary Methods
Supplemental Figure 1C from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Authors: Weiss Sarah A. , Djureinovic Dijana , Jessel Shlomit , Krykbaeva Irina , Zhang Lin , Jilaveanu Lucia , Ralabate Amanda , Johnson Barbara , Levit Neta Shanwetter , Anderson Gail , Zelterman Daniel , Wei Wei , Mahajan Amit , Trifan Ovid , Bosenberg Marcus , Kaech Susan M. , Perry Curtis J. , Damsky William , Gettinger Scott , Sznol Mario , Hurwitz Michael , Kluger Harriet M.
Published: April 2023

Waterfall plots demonstrating the percent change in sum of RECIST v1.1 target lesions compared to baseline. Twenty-five out of 26 patients were included; 1 patient withdrew consent and no follow-up imaging was available for review. The waterfall plots are color-coded by (A) best overall response (PR, SD, PD), (B) cohort (1-6), and (C) tumor type (melanoma, RCC, NSCLC). The majority of patients who experienced disease progression on the study had progression in non-target lesions, as denoted by as asterisk (*), and therefore the percent change in tumor from baseline by RECIST is less than the 20% disease progression threshold for multiple patients who had PD.
Supplementary Table 2 from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Table S2
Supplemental Figure 1A from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Authors: Weiss Sarah A. , Djureinovic Dijana , Jessel Shlomit , Krykbaeva Irina , Zhang Lin , Jilaveanu Lucia , Ralabate Amanda , Johnson Barbara , Levit Neta Shanwetter , Anderson Gail , Zelterman Daniel , Wei Wei , Mahajan Amit , Trifan Ovid , Bosenberg Marcus , Kaech Susan M. , Perry Curtis J. , Damsky William , Gettinger Scott , Sznol Mario , Hurwitz Michael , Kluger Harriet M.
Published: April 2023

Waterfall plots demonstrating the percent change in sum of RECIST v1.1 target lesions compared to baseline. Twenty-five out of 26 patients were included; 1 patient withdrew consent and no follow-up imaging was available for review. The waterfall plots are color-coded by (A) best overall response (PR, SD, PD), (B) cohort (1-6), and (C) tumor type (melanoma, RCC, NSCLC). The majority of patients who experienced disease progression on the study had progression in non-target lesions, as denoted by as asterisk (*), and therefore the percent change in tumor from baseline by RECIST is less than the 20% disease progression threshold for multiple patients who had PD.
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S3 DD durably depletes functional Tregs in human peripheral blood.
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S6 DD depletes Tregs from the tumor microenvironment.
Table S6 from HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor
Authors: Hemming Matthew L. , Coy Shannon , Lin Jia-Ren , Andersen Jessica L. , Przybyl Joanna , Mazzola Emanuele , Abdelhamid Ahmed Amr H. , van de Rijn Matt , Sorger Peter K. , Armstrong Scott A. , Demetri George D. , Santagata Sandro
Published: April 2023

BARX1+/HAND1- Extragastric GIST
Table S4 from HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor
Authors: Hemming Matthew L. , Coy Shannon , Lin Jia-Ren , Andersen Jessica L. , Przybyl Joanna , Mazzola Emanuele , Abdelhamid Ahmed Amr H. , van de Rijn Matt , Sorger Peter K. , Armstrong Scott A. , Demetri George D. , Santagata Sandro
Published: April 2023

GIST Immunohistochemistry Cohort
Table S3 from HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor
Authors: Hemming Matthew L. , Coy Shannon , Lin Jia-Ren , Andersen Jessica L. , Przybyl Joanna , Mazzola Emanuele , Abdelhamid Ahmed Amr H. , van de Rijn Matt , Sorger Peter K. , Armstrong Scott A. , Demetri George D. , Santagata Sandro
Published: April 2023

CyCIF Proliferation Percentages
Supplementary Materials and Methods from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer
Authors: Floberg John M. , Zhang Jin , Muhammad Naoshad , DeWees Todd A. , Inkman Matthew , Chen Kevin , Lin Alexander J. , Rashmi Ramachandran , Jayachandran Kay , Edelson Brian T. , Siegel Barry A. , Dehdashti Farrokh , Grigsby Perry W. , Markovina Stephanie , Schwarz Julie K.
Published: April 2023

Supplemental Material and Methods
Supplementary Figure 1S from Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer
Authors: Floberg John M. , Zhang Jin , Muhammad Naoshad , DeWees Todd A. , Inkman Matthew , Chen Kevin , Lin Alexander J. , Rashmi Ramachandran , Jayachandran Kay , Edelson Brian T. , Siegel Barry A. , Dehdashti Farrokh , Grigsby Perry W. , Markovina Stephanie , Schwarz Julie K.
Published: April 2023

Number of patients in each of the patient cohorts used, and overlap between the cohorts.
Supplementary Table from Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen
Authors: Lewis Calvin D. , Singh Abhay K. , Hsu Fong-Fu , Thotala Dinesh , Hallahan Dennis E. , Kapoor Vaishali
Published: April 2023

Supplementary Table from Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen
Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Authors: Louveau Baptiste , Resche-Rigon Matthieu , Lesimple Thierry , Da Meda Laetitia , Pracht Marc , Baroudjian Barouyr , Delyon Julie , Amini-Adle Mona , Dutriaux Caroline , Reger de Moura Coralie , Sadoux Aurélie , Jouenne Fanélie , Ghrieb Zineb , Vilquin Paul , Bouton Didier , Tibi Annick , Huguet Samuel , Rezai Keyvan , Battistella Maxime , Mourah Samia , Lebbe Céleste
Published: April 2023

Tables S1, S2, S3, S4
Figure S3 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Authors: Louveau Baptiste , Resche-Rigon Matthieu , Lesimple Thierry , Da Meda Laetitia , Pracht Marc , Baroudjian Barouyr , Delyon Julie , Amini-Adle Mona , Dutriaux Caroline , Reger de Moura Coralie , Sadoux Aurélie , Jouenne Fanélie , Ghrieb Zineb , Vilquin Paul , Bouton Didier , Tibi Annick , Huguet Samuel , Rezai Keyvan , Battistella Maxime , Mourah Samia , Lebbe Céleste
Published: April 2023

Figure S3. DNA alterations (mutations and copy number alterations) uncovered in all samples collected before and during treatment (Baseline, after cycle 2 and end of treatment). * indicates samples processed only in mRNA expression and copy number analysis (no NGS data available).
Supplementary Data is word format from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Authors: Johnson Melissa , El-Khoueiry Anthony , Hafez Navid , Lakhani Nehal , Mamdani Hirva , Rodon Jordi , Sanborn Rachel E. , Garcia-Corbacho Javier , Boni Valentina , Stroh Mark , Hannah Alison L. , Wang Song , Castro Henry , Spira Alexander
Published: April 2023

Supplementary Data is word format for production
Figure S1 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Authors: Louveau Baptiste , Resche-Rigon Matthieu , Lesimple Thierry , Da Meda Laetitia , Pracht Marc , Baroudjian Barouyr , Delyon Julie , Amini-Adle Mona , Dutriaux Caroline , Reger de Moura Coralie , Sadoux Aurélie , Jouenne Fanélie , Ghrieb Zineb , Vilquin Paul , Bouton Didier , Tibi Annick , Huguet Samuel , Rezai Keyvan , Battistella Maxime , Mourah Samia , Lebbe Céleste
Published: April 2023

Figure S1. (A) RNA expression and copy number variations in A375 melanoma cell lines resistant to vemurafenib (A375R). RNA expression was normalized according to PPIA, B2M and ACTB gene expression (siRNA: small interfering RNA). (B) Inhibition of CHEK2 at both the mRNA and protein levels in A375 melanoma cell lines resistant to vemurafenib (A375R) transfected with siRNA CHEK2 (50 nM and 100 nM) compared to those transfected with siRNA control (siRNA: small interfering RNA).
Supplementary Data from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Authors: Johnson Melissa , El-Khoueiry Anthony , Hafez Navid , Lakhani Nehal , Mamdani Hirva , Rodon Jordi , Sanborn Rachel E. , Garcia-Corbacho Javier , Boni Valentina , Stroh Mark , Hannah Alison L. , Wang Song , Castro Henry , Spira Alexander
Published: April 2023

Supplementary methods and figures
Supplementary Figure 7 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

supplementary figure
Supplementary Figure 4 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

Figure
Supplementary Figure 3 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

Figure
Supplementary Figure 2 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

Figure
Table S7 from The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
Authors: Zheng Bo , Liu Xiao-Long , Fan Rong , Bai Jian , Wen Hao , Du Lu-Tao , Jiang Guo-Qing , Wang Chun-Ying , Fan Xiao-Tang , Ye Yi-Nong , Qian Yun-Song , Wang Ying-Chao , Liu Gao-Jing , Deng Guo-Hong , Shen Feng , Hu He-Ping , Wang Hui , Zhang Qing-Zheng , Ru Lan-Lan , Zhang Jing , Gao Yan-Hang , Xia Jie , Yan Hua-Dong , Liang Min-Feng , Yu Yan-Long , Sun Fu-Ming , Gao Yu-Jing , Sun Jian , Zhong Chun-Xiu , Wang Yin , Kong Fei , Chen Jin-Ming , Zheng Dan , Yang Yuan , Wang Chuan-Xin , Wu Lin , Hou Jin-Lin , Liu Jing-Feng , Wang Hong-Yang , Chen Lei
Published: April 2023

Table S7
Supplementary Table S1 from Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance
Authors: Beck Lir , Harel Michal , Yu Shun , Markovits Ettai , Boursi Ben , Markel Gal , Geiger Tamar
Published: April 2023

Supplementary Table S1
Table S4 from The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
Authors: Zheng Bo , Liu Xiao-Long , Fan Rong , Bai Jian , Wen Hao , Du Lu-Tao , Jiang Guo-Qing , Wang Chun-Ying , Fan Xiao-Tang , Ye Yi-Nong , Qian Yun-Song , Wang Ying-Chao , Liu Gao-Jing , Deng Guo-Hong , Shen Feng , Hu He-Ping , Wang Hui , Zhang Qing-Zheng , Ru Lan-Lan , Zhang Jing , Gao Yan-Hang , Xia Jie , Yan Hua-Dong , Liang Min-Feng , Yu Yan-Long , Sun Fu-Ming , Gao Yu-Jing , Sun Jian , Zhong Chun-Xiu , Wang Yin , Kong Fei , Chen Jin-Ming , Zheng Dan , Yang Yuan , Wang Chuan-Xin , Wu Lin , Hou Jin-Lin , Liu Jing-Feng , Wang Hong-Yang , Chen Lei
Published: April 2023

Table S4
Table S2 from The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
Authors: Zheng Bo , Liu Xiao-Long , Fan Rong , Bai Jian , Wen Hao , Du Lu-Tao , Jiang Guo-Qing , Wang Chun-Ying , Fan Xiao-Tang , Ye Yi-Nong , Qian Yun-Song , Wang Ying-Chao , Liu Gao-Jing , Deng Guo-Hong , Shen Feng , Hu He-Ping , Wang Hui , Zhang Qing-Zheng , Ru Lan-Lan , Zhang Jing , Gao Yan-Hang , Xia Jie , Yan Hua-Dong , Liang Min-Feng , Yu Yan-Long , Sun Fu-Ming , Gao Yu-Jing , Sun Jian , Zhong Chun-Xiu , Wang Yin , Kong Fei , Chen Jin-Ming , Zheng Dan , Yang Yuan , Wang Chuan-Xin , Wu Lin , Hou Jin-Lin , Liu Jing-Feng , Wang Hong-Yang , Chen Lei
Published: April 2023

Table S2
Table S1 from The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
Authors: Zheng Bo , Liu Xiao-Long , Fan Rong , Bai Jian , Wen Hao , Du Lu-Tao , Jiang Guo-Qing , Wang Chun-Ying , Fan Xiao-Tang , Ye Yi-Nong , Qian Yun-Song , Wang Ying-Chao , Liu Gao-Jing , Deng Guo-Hong , Shen Feng , Hu He-Ping , Wang Hui , Zhang Qing-Zheng , Ru Lan-Lan , Zhang Jing , Gao Yan-Hang , Xia Jie , Yan Hua-Dong , Liang Min-Feng , Yu Yan-Long , Sun Fu-Ming , Gao Yu-Jing , Sun Jian , Zhong Chun-Xiu , Wang Yin , Kong Fei , Chen Jin-Ming , Zheng Dan , Yang Yuan , Wang Chuan-Xin , Wu Lin , Hou Jin-Lin , Liu Jing-Feng , Wang Hong-Yang , Chen Lei
Published: April 2023

Table S1
Supplemental Tables from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Authors: Chang Jason C. , Offin Michael , Falcon Christina , Brown David , Houck-Loomis Brian R. , Meng Fanli , Rudneva Vasilisa A. , Won Helen H. , Amir Sharon , Montecalvo Joseph , Desmeules Patrice , Kadota Kyuichi , Adusumilli Prasad S. , Rusch Valerie W. , Teed Sarah , Sabari Joshua K. , Benayed Ryma , Nafa Khedoudja , Borsu Laetitia , Li Bob T. , Schram Alison M. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Drilon Alexander , Rekhtman Natasha
Published: April 2023

Supplemental Tables 1-11
Supplemental Methods 1 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Authors: Chang Jason C. , Offin Michael , Falcon Christina , Brown David , Houck-Loomis Brian R. , Meng Fanli , Rudneva Vasilisa A. , Won Helen H. , Amir Sharon , Montecalvo Joseph , Desmeules Patrice , Kadota Kyuichi , Adusumilli Prasad S. , Rusch Valerie W. , Teed Sarah , Sabari Joshua K. , Benayed Ryma , Nafa Khedoudja , Borsu Laetitia , Li Bob T. , Schram Alison M. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Drilon Alexander , Rekhtman Natasha
Published: April 2023

Supplemental Methods 1
Supplementary Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Autio Karen , Golan Talia , Dobrenkov Konstantin , Chartash Elliot , Chen Qiusheng , Wnek Richard , Long Georgina V.
Published: April 2023

Supplementary Caption
Supplementary Tables from Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment
Authors: Vardaki Ioulia , Corn Paul , Gentile Emanuela , Song Jian H. , Madan Namrata , Hoang Anh , Parikh Nila , Guerra Leah , Lee Yu-Chen , Lin Song-Chang , Yu Guoyu , Santos Elmer , Melancon Marites P. , Troncoso Patricia , Navone Nora , Gallick Gary E. , Efstathiou Eleni , Subudhi Sumit K. , Lin Sue-Hwa , Logothetis Christopher J. , Panaretakis Theocharis
Published: April 2023

Supp Tables 1-3
Supplementary Data from Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment
Authors: Vardaki Ioulia , Corn Paul , Gentile Emanuela , Song Jian H. , Madan Namrata , Hoang Anh , Parikh Nila , Guerra Leah , Lee Yu-Chen , Lin Song-Chang , Yu Guoyu , Santos Elmer , Melancon Marites P. , Troncoso Patricia , Navone Nora , Gallick Gary E. , Efstathiou Eleni , Subudhi Sumit K. , Lin Sue-Hwa , Logothetis Christopher J. , Panaretakis Theocharis
Published: April 2023

Materials and Methods
Supplementary Table S2 from Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Authors: Zengin Zeynep B. , Weipert Caroline , Salgia Nicholas J. , Dizman Nazli , Hsu Joann , Meza Luis , Chehrazi-Raffle Alexander , Muddasani Ramya , Salgia Sabrina , Malhotra Jasnoor , Chawla Neal , Philip Errol J. , Kiedrowski Lesli , Maughan Benjamin L. , Rathi Nityam , Goel Divyam , Choueiri Toni K. , Agarwal Neeraj , Pal Sumanta K.
Published: April 2023

Patient characteristics
Supplementary Figure S1 from Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Authors: Zengin Zeynep B. , Weipert Caroline , Salgia Nicholas J. , Dizman Nazli , Hsu Joann , Meza Luis , Chehrazi-Raffle Alexander , Muddasani Ramya , Salgia Sabrina , Malhotra Jasnoor , Chawla Neal , Philip Errol J. , Kiedrowski Lesli , Maughan Benjamin L. , Rathi Nityam , Goel Divyam , Choueiri Toni K. , Agarwal Neeraj , Pal Sumanta K.
Published: April 2023

Change in alterations across time points
Table S3 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Growth inhibition IC50 data of LXH254 in CCLE panel
Supplementary Data from Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
Authors: Kazi Aslamuzzaman , Chen Liwei , Xiang Shengyan , Vangipurapu Rajanikanth , Yang Hua , Beato Francisca , Fang Bin , Williams Terence M. , Husain Kazim , Underwood Patrick , Fleming Jason B. , Malafa Mokenge , Welsh Eric A. , Koomen John , Trevino José , Sebti Saïd M.
Published: April 2023

Supplementary Table 1
Table S2 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Results of Kinativ studies using LXH254 in HCT 116 cells
Supp Figures from Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
Authors: Kazi Aslamuzzaman , Chen Liwei , Xiang Shengyan , Vangipurapu Rajanikanth , Yang Hua , Beato Francisca , Fang Bin , Williams Terence M. , Husain Kazim , Underwood Patrick , Fleming Jason B. , Malafa Mokenge , Welsh Eric A. , Koomen John , Trevino José , Sebti Saïd M.
Published: April 2023

Supplementary Figures
Figure S5 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Supplementary Figure 5. Model for LXH254 interactions with RAF monomers and dimers (A). (B) Upper panel, simulated structure of ARAF (green) overlaid on the structure of BRAF (blue). LXH254 interacting with ARAF is shown in yellow and with BRAF in purple. (B) Lower panel, enhanced view of hydrogen bond interactions between LXH254 (purple) and the backbone carbonyl of F595 of BRAF (Blue) and LXH254 (yellow) and backbone carbonyl of ARAF (green).
Figure S4 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Supplementary Figure 4. Growth of individual tumors shown in Fig. 7A-C are given for HCT 116 (A), MIA PaCa-2 (B) and MEL-JUSO (C) cells.
Figure S2 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Supplementary Figure 2. Western blot analysis of CRISPR-CAS9 cell lines and exogenously expressed ARAF variants used in experiments shown in Figures 3-7.
Supplementary Figures from Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
Authors: Krijgsman Oscar , Kemper Kristel , Boshuizen Julia , Vredevoogd David W. , Rozeman Elisa A. , Ibanez Molero Sofia , de Bruijn Beaunelle , Cornelissen-Steijger Paulien , Shahrabi Aida , Del Castillo Velasco-Herrera Martin , Song Ji-Ying , Ligtenberg Maarten A. , Kluin Roelof J.C. , Kuilman Thomas , Ross-Macdonald Petra , Haanen John B.A.G. , Adams David J. , Blank Christian U. , Peeper Daniel S.
Published: April 2023

Supplementary Figures
Supplementary Figure legends from Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
Authors: Krijgsman Oscar , Kemper Kristel , Boshuizen Julia , Vredevoogd David W. , Rozeman Elisa A. , Ibanez Molero Sofia , de Bruijn Beaunelle , Cornelissen-Steijger Paulien , Shahrabi Aida , Del Castillo Velasco-Herrera Martin , Song Ji-Ying , Ligtenberg Maarten A. , Kluin Roelof J.C. , Kuilman Thomas , Ross-Macdonald Petra , Haanen John B.A.G. , Adams David J. , Blank Christian U. , Peeper Daniel S.
Published: April 2023

Legends for the supplementary figures
Table S1 from Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma
Authors: Andrews David W. , Judy Kevin D. , Scott Charles B. , Garcia Samantha , Harshyne Larry A. , Kenyon Lawrence , Talekar Kiran , Flanders Adam , Atsina Kofi-Buaku , Kim Lyndon , Martinez Nina , Shi Wenyin , Werner-Wasik Maria , Liu Haisong , Prosniak Mikhail , Curtis Mark , Kean Rhonda , Ye Donald Y. , Bongiorno Emily , Sauma Sami , Exley Mark A. , Pigott Kara , Hooper D. Craig
Published: April 2023

Determination of severity for adverse events
Supplementary ctDNA Data from Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Authors: Bardia Aditya , Hurvitz Sara A. , DeMichele Angela , Clark Amy S. , Zelnak Amelia , Yardley Denise A. , Karuturi Meghan , Sanft Tara , Blau Sibel , Hart Lowell , Ma Cynthia , Rugo Hope S. , Purkayastha Das , Moulder Stacy
Published: April 2023

Raw ctDNA data
Supplementary Figure S6 from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Authors: Hunter Anthony M. , Newman Hannah , Dezern Amy E. , Steensma David P. , Niyongere Sandrine , Roboz Gail J. , Mo Qianxing , Chan Onyee , Gerds Aaron , Sallman David A. , Dominguez-Viqueira William , Letson Christopher , Balasis Maria E. , Ball Markus , Kruer Traci , Zhang Hailing , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S. , Padron Eric
Published: April 2023

Supplementary Figure S6 compares various metrics assessed at time of necropsy in patient-derived xenograft mice.
Suppl Figure from Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Authors: Bardia Aditya , Hurvitz Sara A. , DeMichele Angela , Clark Amy S. , Zelnak Amelia , Yardley Denise A. , Karuturi Meghan , Sanft Tara , Blau Sibel , Hart Lowell , Ma Cynthia , Rugo Hope S. , Purkayastha Das , Moulder Stacy
Published: April 2023

Supplemental Figure 1. ER, PI3K/mTOR, and CDK4/6 Pathways in HR+ Breast Cancer Supplemental Figure 2. Median Ctrough From Cycle 1 Day 15 in Cohorts A and B. Supplemental Figure 3. Time to Progression or Time on Study Treatment Supplemental Figure 4. Baseline ctDNA Mutations and Time to Disease Progression or Death
Supplementary Figure S3 from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Authors: Hunter Anthony M. , Newman Hannah , Dezern Amy E. , Steensma David P. , Niyongere Sandrine , Roboz Gail J. , Mo Qianxing , Chan Onyee , Gerds Aaron , Sallman David A. , Dominguez-Viqueira William , Letson Christopher , Balasis Maria E. , Ball Markus , Kruer Traci , Zhang Hailing , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S. , Padron Eric
Published: April 2023

Supplementary Figure S3 depicts the overall survival of the total study population.
Supplementary Data from Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer
Authors: Lafferty Adam , O'Farrell Alice C. , Migliardi Giorgia , Khemka Niraj , Lindner Andreas U. , Sassi Francesco , Zanella Eugenia R. , Salvucci Manuela , Vanderheyden Evy , Modave Elodie , Boeckx Bram , Halang Luise , Betge Johannes , Ebert Matthias P.A. , Dicker Patrick , Argilés Guillem , Tabernero Josep , Dienstmann Rodrigo , Medico Enzo , Lambrechts Diether , Bertotti Andrea , Isella Claudio , Trusolino Livio , Prehn Jochen H.M. , Byrne Annette T.
Published: April 2023

Supplementary Figures S1 - S8 and Table S1. Fig S1: Analysis of copy number burden in a PDX population trial of REG treated mCRC PDXs. Fig S2: Effect of REG on microvessel density and proliferation according to CNA cluster. Fig S3 - S6: BCL-2 family profiling of mCRC PDX models via quantitative Western blotting. Fig S7: RPPA protein scores indicating proteins' association with the PDX models' response to REG. Fig S8: Western blot validation of differential EPHA2 protein expression between REG post- and pre-treatment progressor and non-progressor PDX models. Table S1: List of antibodies and dilution factors used against desired targets in RPPA analysis.
Figure S3 from Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Authors: Do Khanh T. , Kochupurakkal Bose , Kelland Sarah , de Jonge Adrienne , Hedglin Jennifer , Powers Allison , Quinn Nicholas , Gannon Courtney , Vuong Loan , Parmar Kalindi , Lazaro Jean-Bernard , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Pharmacokinetic Data
Supplementary table ST1 from Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
Authors: Turner Philip G. , Jain Suneil , Cole Aidan , Grey Arthur , Mitchell Darren , Prise Kevin M. , Hounsell Alan R. , McGarry Conor K. , Biggart Sandra , O'Sullivan Joe M.
Published: April 2023

Supplementary table ST1 shows adverse events in all domains other than GI, GU and haematological
Supplementary Figure S10 from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Authors: Sztupinszki Zsofia , Diossy Miklos , Borcsok Judit , Prosz Aurel , Cornelius Nanna , Kjeldsen Maj K. , Mirza Mansoor R. , Szallasi Zoltan
Published: April 2023

Comparison of WGS vs WES HRDetect
Supplementary Table 6 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Authors: Gordon Max J. , Kaempf Andy , Sitlinger Andrea , Shouse Geoffrey , Mei Matthew , Brander Danielle M. , Salous Tareq , Hill Brian T. , Alqahtani Hamood , Choi Michael , Churnetski Michael C. , Cohen Jonathon B. , Stephens Deborah M. , Siddiqi Tanya , Rivera Xavier , Persky Daniel , Wisniewski Paul , Patel Krish , Shadman Mazyar , Park Byung , Danilov Alexey V.
Published: April 2023

S Table 6
Figure S5 from Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non–Small Cell Lung Cancer
Authors: Porciuncula Angelo , Morgado Micaela , Gupta Richa , Syrigos Kostas , Meehan Robert , Zacharek Sima J. , Frederick Joshua P. , Schalper Kurt A.
Published: April 2023

Supplementary Figure S5
Supplementary Table 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Hajda Jacek , Leuchs Barbara , Angelova Assia L. , Frehtman Veronika , Rommelaere Jean , Mertens Mieke , Pilz Maximilian , Kieser Meinhard , Krebs Ottheinz , Dahm Michael , Huber Bernard , Engeland Christine E. , Mavratzas Athanasios , Hohmann Nicolas , Schreiber Jutta , Jäger Dirk , Halama Niels , Sedlaczek Oliver , Gaida Matthias M. , Daniel Volker , Springfeld Christoph , Ungerechts Guy
Published: April 2023

Supplementary Table 2
Supplementary Figure 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Authors: Hajda Jacek , Leuchs Barbara , Angelova Assia L. , Frehtman Veronika , Rommelaere Jean , Mertens Mieke , Pilz Maximilian , Kieser Meinhard , Krebs Ottheinz , Dahm Michael , Huber Bernard , Engeland Christine E. , Mavratzas Athanasios , Hohmann Nicolas , Schreiber Jutta , Jäger Dirk , Halama Niels , Sedlaczek Oliver , Gaida Matthias M. , Daniel Volker , Springfeld Christoph , Ungerechts Guy
Published: April 2023

Virus shedding in urine and saliva
Table S2 from Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors
Authors: Thompson Patricia A. , Huang Chuan , Yang Jie , Wertheim Betsy C. , Roe Denise , Zhang Xiaoyue , Ding Jie , Chalasani Pavani , Preece Christina , Martinez Jessica , Chow H.-H. Sherry , Stopeck Alison T.
Published: April 2023

Table showing descriptive statistics for three collagen features (length, width, and straightness) at the baseline measure.
Figure S9. from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Plasma metabolomics principal coordinate analysis
Figure S10. from Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study
Authors: de Clercq Nicolien C. , van den Ende Tom , Prodan Andrei , Hemke Robert , Davids Mark , Pedersen Helle K. , Nielsen Henrik B. , Groen A.K. , de Vos Willem M. , van Laarhoven Hanneke W.M. , Nieuwdorp Max
Published: April 2023

Top 15 metabolites week 4
STable1 from Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Authors: Steele Nina G. , Biffi Giulia , Kemp Samantha B. , Zhang Yaqing , Drouillard Donovan , Syu LiJyun , Hao Yuan , Oni Tobiloba E. , Brosnan Erin , Elyada Ela , Doshi Abhishek , Hansma Christa , Espinoza Carlos , Abbas Ahmed , The Stephanie , Irizarry-Negron Valerie , Halbrook Christopher J. , Franks Nicole E. , Hoffman Megan T. , Brown Kristee , Carpenter Eileen S. , Nwosu Zeribe C. , Johnson Craig , Lima Fatima , Anderson Michelle A. , Park Youngkyu , Crawford Howard C. , Lyssiotis Costas A. , Frankel Timothy L. , Rao Arvind , Bednar Filip , Dlugosz Andrzej A. , Preall Jonathan B. , Tuveson David A. , Allen Benjamin L. , Pasca di Magliano Marina
Published: April 2023

Table of antibodies.
SFigure2 from Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Authors: Steele Nina G. , Biffi Giulia , Kemp Samantha B. , Zhang Yaqing , Drouillard Donovan , Syu LiJyun , Hao Yuan , Oni Tobiloba E. , Brosnan Erin , Elyada Ela , Doshi Abhishek , Hansma Christa , Espinoza Carlos , Abbas Ahmed , The Stephanie , Irizarry-Negron Valerie , Halbrook Christopher J. , Franks Nicole E. , Hoffman Megan T. , Brown Kristee , Carpenter Eileen S. , Nwosu Zeribe C. , Johnson Craig , Lima Fatima , Anderson Michelle A. , Park Youngkyu , Crawford Howard C. , Lyssiotis Costas A. , Frankel Timothy L. , Rao Arvind , Bednar Filip , Dlugosz Andrzej A. , Preall Jonathan B. , Tuveson David A. , Allen Benjamin L. , Pasca di Magliano Marina
Published: April 2023

SFigure2
SFigure1 from Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Authors: Steele Nina G. , Biffi Giulia , Kemp Samantha B. , Zhang Yaqing , Drouillard Donovan , Syu LiJyun , Hao Yuan , Oni Tobiloba E. , Brosnan Erin , Elyada Ela , Doshi Abhishek , Hansma Christa , Espinoza Carlos , Abbas Ahmed , The Stephanie , Irizarry-Negron Valerie , Halbrook Christopher J. , Franks Nicole E. , Hoffman Megan T. , Brown Kristee , Carpenter Eileen S. , Nwosu Zeribe C. , Johnson Craig , Lima Fatima , Anderson Michelle A. , Park Youngkyu , Crawford Howard C. , Lyssiotis Costas A. , Frankel Timothy L. , Rao Arvind , Bednar Filip , Dlugosz Andrzej A. , Preall Jonathan B. , Tuveson David A. , Allen Benjamin L. , Pasca di Magliano Marina
Published: April 2023

SFigure1
Supplementary Table 1 from Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Authors: Lei Ming , Siemers Nathan O. , Pandya Dimple , Chang Han , Sanchez Teresa , Harbison Christopher , Szabo Peter M. , Janjigian Yelena , Ott Patrick A. , Sharma Padmanee , Bendell Johanna , Evans Thomas R. Jeffry , de Braud Filippo , Chau Ian , Boyd Zachary
Published: April 2023

Additional details on CPS scoring done by Agilent-certified pathologists
Table.S7 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Authors: Lone Waseem , Bouska Alyssa , Sharma Sunandini , Amador Catalina , Saumyaranjan Mallick , Herek Tyler A. , Heavican Tayla B. , Yu Jiayu , Lim Soon Thye , Ong Choon Kiat , Slack Graham W. , Savage Kerry J. , Rosenwald Andreas , Ott German , Cook James R. , Feldman Andrew L. , Rimsza Lisa M. , McKeithan Timothy W. , Greiner Timothy C. , Weisenburger Dennis D. , Melle Federica , Motta Giovanna , Pileri Stefano , Vose Julie M. , Chan Wing C. , Iqbal Javeed
Published: April 2023

Table S7. Significant signaling pathways associated with the differentially expressed miRNA between PTCL entities and their corresponding normal counterpart
Table.S1 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Authors: Lone Waseem , Bouska Alyssa , Sharma Sunandini , Amador Catalina , Saumyaranjan Mallick , Herek Tyler A. , Heavican Tayla B. , Yu Jiayu , Lim Soon Thye , Ong Choon Kiat , Slack Graham W. , Savage Kerry J. , Rosenwald Andreas , Ott German , Cook James R. , Feldman Andrew L. , Rimsza Lisa M. , McKeithan Timothy W. , Greiner Timothy C. , Weisenburger Dennis D. , Melle Federica , Motta Giovanna , Pileri Stefano , Vose Julie M. , Chan Wing C. , Iqbal Javeed
Published: April 2023

Table S1. Patient Charactertistics and their mi-EP platform type
Figure S3 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Authors: Arai Hiroyuki , Elliott Andrew , Xiu Joanne , Wang Jingyuan , Battaglin Francesca , Kawanishi Natsuko , Soni Shivani , Zhang Wu , Millstein Joshua , Sohal Davendra , Goldberg Richard M. , Hall Michael J. , Scott Aaron J. , Khushman Moh'd , Hwang Jimmy J. , Lou Emil , Weinberg Benjamin A. , Marshall John L. , Lockhart Albert C. , Stafford Phillip , Zhang Jian , Moretto Roberto , Cremolini Chiara , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

The frequency of DDR pathways alteration by RAS status